SEC Form 4 · accession 0000899243-18-016879
CRISPR Therapeutics AG · CRSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James R. Kasinger
Officer — General Counsel and Secretary
Period of report
Jun 15, 2018
Accepted (ET)
Jun 15, 2018 · 9:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001674416
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $59.31 | Jun 15, 2018 | A | 32,000 | A | — | Jun 15, 2028 | Common Shares | 32,000 | 32,000 | D |
Explanation of responses
- F1This option was granted on June 15, 2018 with respect to 32,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments.